交易 Rigel - RIGL CFD
新增到我的最愛- 摘要
- 曆史數據
- 活動
- 盈虧控制
- 資産負債表
- 現金流
交易條件
價差 | 0.05 | ||||||||
多頭倉位隔夜費用
多頭隔夜費用
前往平台 | -0.026179% | ||||||||
空頭倉位隔夜費用
空頭隔夜費用
前往平台 | 0.003957% | ||||||||
隔夜費時間 | 21:00 (UTC) | ||||||||
最小成交量 | 1 | ||||||||
貨幣 | USD | ||||||||
保證金 | 5% | ||||||||
股票交易 | United States of America | ||||||||
交易委員會 | 0% |
*Information provided by Capital.com
Rigel Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
“B”分數表示相對 ESG 表現良好,公開報告重要 ESG 數據的透明度高於平均水平。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 拋售 | 自訂 | 變化 (%) | 打開 | 最高 | 最小 |
---|---|---|---|---|---|---|
Mar 27, 2024 | 1.46 | 0.06 | 4.29% | 1.40 | 1.47 | 1.38 |
Mar 26, 2024 | 1.40 | -0.04 | -2.78% | 1.44 | 1.45 | 1.40 |
Mar 25, 2024 | 1.41 | 0.00 | 0.00% | 1.41 | 1.43 | 1.38 |
Mar 22, 2024 | 1.40 | 0.00 | 0.00% | 1.40 | 1.44 | 1.39 |
Mar 21, 2024 | 1.42 | 0.03 | 2.16% | 1.39 | 1.44 | 1.38 |
Mar 20, 2024 | 1.39 | 0.04 | 2.96% | 1.35 | 1.41 | 1.32 |
Mar 19, 2024 | 1.35 | 0.04 | 3.05% | 1.31 | 1.37 | 1.30 |
Mar 18, 2024 | 1.31 | 0.01 | 0.77% | 1.30 | 1.33 | 1.28 |
Mar 15, 2024 | 1.33 | 0.05 | 3.91% | 1.28 | 1.40 | 1.28 |
Mar 14, 2024 | 1.31 | -0.11 | -7.75% | 1.42 | 1.43 | 1.29 |
Mar 13, 2024 | 1.42 | -0.04 | -2.74% | 1.46 | 1.48 | 1.42 |
Mar 12, 2024 | 1.47 | -0.02 | -1.34% | 1.49 | 1.51 | 1.46 |
Mar 11, 2024 | 1.49 | -0.06 | -3.87% | 1.55 | 1.59 | 1.48 |
Mar 8, 2024 | 1.54 | 0.02 | 1.32% | 1.52 | 1.56 | 1.48 |
Mar 7, 2024 | 1.51 | -0.04 | -2.58% | 1.55 | 1.61 | 1.49 |
Mar 6, 2024 | 1.54 | 0.03 | 1.99% | 1.51 | 1.70 | 1.50 |
Mar 5, 2024 | 1.44 | -0.02 | -1.37% | 1.46 | 1.48 | 1.41 |
Mar 4, 2024 | 1.44 | -0.09 | -5.88% | 1.53 | 1.53 | 1.43 |
Mar 1, 2024 | 1.52 | 0.02 | 1.33% | 1.50 | 1.61 | 1.46 |
Feb 29, 2024 | 1.48 | -0.06 | -3.90% | 1.54 | 1.55 | 1.44 |
Rigel Events
時間 (UTC) | 國家 | 事件 |
---|---|---|
Tuesday, April 30, 2024 | ||
時間 (UTC) 20:00 | 國家 US
| 事件 Q1 2024 Rigel Pharmaceuticals Inc Earnings Release Q1 2024 Rigel Pharmaceuticals Inc Earnings ReleaseForecast(預報) -返回 - |
Friday, May 24, 2024 | ||
時間 (UTC) 14:30 | 國家 US
| 事件 Rigel Pharmaceuticals Inc Annual Shareholders Meeting Rigel Pharmaceuticals Inc Annual Shareholders MeetingForecast(預報) -返回 - |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 120.242 | 149.236 | 108.621 | 59.288 | 44.509 |
收入 | 120.242 | 149.236 | 108.621 | 59.288 | 44.509 |
總營業費用 | 175.792 | 161.732 | 137.594 | 128.379 | 117.192 |
銷售/一般/行政費用,總計 | 112.451 | 91.891 | 76.598 | 74.588 | 70.002 |
研究與開發 | 60.272 | 65.237 | 60.101 | 52.885 | 46.903 |
異常費用(收入) | 1.32 | 3.521 | 0 | ||
營業收入 | -55.55 | -12.496 | -28.973 | -69.091 | -72.683 |
利息收入(費用),非經營淨值 | -3.023 | -4.813 | -0.771 | 2.197 | 2.203 |
Gain (Loss) on Sale of Assets | 0 | 0 | |||
稅前淨收入 | -58.573 | -17.309 | -29.744 | -66.894 | -70.48 |
稅後淨收入 | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
未計算非常項目前的淨收益 | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
淨收入 | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
普通股股東可獲收益 (不含非經常性項目) | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
普通股股東可獲收益 (含非經常性項目) | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
攤薄淨收入 | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
攤薄後加權平均股 | 172.406 | 170.492 | 168.754 | 167.4 | 160.529 |
扣除特別項目的每股攤薄盈利 | -0.33974 | -0.10507 | -0.17626 | -0.39961 | -0.43905 |
每股正常攤薄盈利 | -0.33208 | -0.09165 | -0.17626 | -0.39961 | -0.43905 |
非常規項目總計 | |||||
收入成本,共計 | 1.749 | 1.083 | 0.895 | 0.906 | 0.287 |
毛利 | 118.493 | 148.153 | 107.726 | 58.382 | 44.222 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 26.886 | 26.07 | 51.278 | 22.41 | 29.819 |
收入 | 26.886 | 26.07 | 51.278 | 22.41 | 29.819 |
收入成本,共計 | 1.075 | 0.977 | 0.342 | 0.25 | 1.036 |
毛利 | 25.811 | 25.093 | 50.936 | 22.16 | 28.783 |
總營業費用 | 32.153 | 38.795 | 49.199 | 40.813 | 42.784 |
銷售/一般/行政費用,總計 | 26.306 | 27.729 | 32.172 | 25.897 | 26.981 |
研究與開發 | 4.772 | 10.089 | 15.365 | 14.666 | 14.767 |
營業收入 | -5.267 | -12.725 | 2.079 | -18.403 | -12.965 |
利息收入(費用),非經營淨值 | -1.333 | -0.811 | -0.678 | -0.634 | -0.527 |
稅前淨收入 | -6.6 | -13.536 | 1.401 | -19.037 | -13.492 |
稅後淨收入 | -6.6 | -13.536 | 1.401 | -19.037 | -13.492 |
未計算非常項目前的淨收益 | -6.6 | -13.536 | 1.401 | -19.037 | -13.492 |
淨收入 | -6.6 | -13.536 | 1.401 | -19.037 | -13.492 |
普通股股東可獲收益 (不含非經常性項目) | -6.6 | -13.536 | 1.401 | -19.037 | -13.492 |
普通股股東可獲收益 (含非經常性項目) | -6.6 | -13.536 | 1.401 | -19.037 | -13.492 |
攤薄淨收入 | -6.6 | -13.536 | 1.401 | -19.037 | -13.492 |
攤薄後加權平均股 | 173.748 | 173.568 | 140.1 | 172.836 | 172.147 |
扣除特別項目的每股攤薄盈利 | -0.03799 | -0.07799 | 0.01 | -0.11014 | -0.07837 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.03799 | -0.07799 | 0.01942 | -0.11014 | -0.07837 |
異常費用(收入) | 1.32 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 115.903 | 154.467 | 88.983 | 119.005 | 136.987 |
現金和短期投資 | 58.206 | 124.967 | 57.327 | 98.078 | 128.537 |
現金等價物 | 24.459 | 18.89 | 30.373 | 22.521 | 76.322 |
短期投資 | 33.747 | 106.077 | 26.954 | 75.557 | 52.215 |
應收賬款總額,淨額 | 40.32 | 15.472 | 15.973 | 10.111 | 4.077 |
應收賬款 - 貿易,淨額 | 40.32 | 15.472 | 15.973 | 10.111 | 4.077 |
預付的費用 | 8.259 | 7.412 | 14.045 | 9.462 | 3.479 |
總資産 | 134.279 | 167.328 | 110.378 | 147.569 | 139.109 |
物業/廠房/設備,總計 - 淨額 | 2.787 | 11.887 | 20.571 | 27.868 | 1.387 |
物業/廠房/設備,總計 - 總額 | 13.594 | 26.438 | 34.247 | 40.913 | 14.241 |
累計折舊,總計 | -10.807 | -14.551 | -13.676 | -13.045 | -12.854 |
其他長期資産,總計 | 0.64 | 0.974 | 0.824 | 0.696 | 0.735 |
流動負債總額 | 65.211 | 63.554 | 40.841 | 58.212 | 27.734 |
應付賬款 | 22.508 | 3.795 | 3.707 | 4.152 | 6.391 |
預提費用 | 24.192 | 43.657 | 34.116 | 28.772 | 20.313 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 18.511 | 16.102 | 3.018 | 25.288 | 1.03 |
負債總額 | 147.895 | 136.954 | 76.352 | 93.754 | 29.232 |
長期債務總額 | 39.448 | 19.914 | 19.815 | 9.81 | 0 |
其他負債,總計 | 43.236 | 53.486 | 15.696 | 25.732 | 1.498 |
股權 | -13.616 | 30.374 | 34.026 | 53.815 | 109.877 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
普通股 | 0.174 | 0.172 | 0.169 | 0.168 | 0.167 |
額外實收資本 | 1368.82 | 1354.19 | 1339.83 | 1329.85 | 1319.07 |
留存收益(累計赤字) | -1382.46 | -1323.89 | -1305.97 | -1276.23 | -1209.33 |
其他權益,總計 | -0.153 | -0.102 | -0.004 | 0.023 | -0.024 |
總負債和股東權益 | 134.279 | 167.328 | 110.378 | 147.569 | 139.109 |
已發行普通股總數 | 173.399 | 171.602 | 169.317 | 167.988 | 167.172 |
總庫存 | 9.118 | 6.616 | 1.638 | 1.354 | 0.894 |
長期債務 | 39.448 | 19.914 | 19.815 | 9.81 | |
無形資産,淨額 | 14.949 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 95.024 | 100.925 | 106.972 | 115.903 | 110.44 |
現金和短期投資 | 62.351 | 64.357 | 58.662 | 58.206 | 81.642 |
現金等價物 | 45.414 | 48.812 | 40.285 | 24.459 | 29.866 |
短期投資 | 16.937 | 15.545 | 18.377 | 33.747 | 51.776 |
應收賬款總額,淨額 | 23.546 | 20.819 | 29.366 | 40.32 | 15.525 |
應收賬款 - 貿易,淨額 | 23.546 | 20.819 | 29.366 | 40.32 | 15.525 |
總庫存 | 6.112 | 10.782 | 11.077 | 9.118 | 7.116 |
預付的費用 | 3.015 | 4.967 | 7.867 | 8.259 | 6.157 |
總資産 | 115.324 | 117.091 | 123.612 | 134.279 | 115.609 |
物業/廠房/設備,總計 - 淨額 | 1.198 | 1.212 | 1.417 | 2.787 | 4.685 |
其他長期資産,總計 | 4.956 | 0.541 | 0.542 | 0.64 | 0.484 |
流動負債總額 | 48.273 | 44.023 | 45.518 | 65.211 | 47.265 |
應付賬款 | 7.999 | 5.24 | 6.295 | 22.508 | 2.721 |
預提費用 | 19.55 | 18.044 | 18.146 | 24.192 | 37.263 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 20.724 | 20.739 | 21.077 | 18.511 | 7.281 |
負債總額 | 147.158 | 145.206 | 147.869 | 147.895 | 135.443 |
長期債務總額 | 59.659 | 59.574 | 59.484 | 39.448 | 39.468 |
長期債務 | 59.659 | 59.574 | 59.484 | 39.448 | 39.468 |
其他負債,總計 | 39.226 | 41.609 | 42.867 | 43.236 | 48.71 |
股權 | -31.834 | -28.115 | -24.257 | -13.616 | -19.834 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
普通股 | 0.175 | 0.175 | 0.174 | 0.174 | 0.173 |
額外實收資本 | 1376.29 | 1374.33 | 1371.59 | 1368.82 | 1364.14 |
留存收益(累計赤字) | -1408.29 | -1402.59 | -1395.99 | -1382.46 | -1383.86 |
其他權益,總計 | -0.015 | -0.025 | -0.027 | -0.153 | -0.286 |
總負債和股東權益 | 115.324 | 117.091 | 123.612 | 134.279 | 115.609 |
已發行普通股總數 | 174.367 | 174.358 | 173.666 | 173.399 | 172.836 |
無形資産,淨額 | 14.146 | 14.413 | 14.681 | 14.949 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
淨收入/起跑線 | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
經營活動産生的現金 | -73.758 | 5.878 | -52.185 | -41.51 | -58.826 |
經營活動産生的現金 | 0.998 | 1.162 | 0.706 | 0.683 | 0.594 |
非現金物品 | 12.866 | 12.912 | 7.175 | 8.042 | 6.938 |
營運資金的變化 | -29.049 | 9.718 | -30.322 | 16.659 | 4.122 |
投資活動産生的現金 | 72.777 | -80.036 | 47.466 | -23.656 | 24.964 |
資本支出 | -0.45 | -0.627 | -1.262 | -1.455 | -1.106 |
其他投資現金流量項目,總計 | 73.227 | -79.409 | 48.728 | -22.201 | 26.07 |
融資活動産生的現金 | 6.55 | 62.675 | 12.571 | 11.365 | 71.894 |
股票的發行(報廢),淨額 | 2.124 | 4.775 | 2.596 | 1.576 | 71.894 |
現金淨變化 | 5.569 | -11.483 | 7.852 | -53.801 | 38.032 |
已付現金利息 | 2.495 | 1.5 | 1.18 | 0.137 | |
債務的發行(退還),淨額 | 19.542 | 0 | 9.975 | 9.789 | |
融資現金流項目 | -15.116 | 57.9 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -13.536 | -58.573 | -59.974 | -40.937 | -27.445 |
Cash From Operating Activities | -4.074 | -73.758 | -51.849 | -38.548 | -25.637 |
Cash From Operating Activities | 0.357 | 0.998 | 0.714 | 0.474 | 0.237 |
Non-Cash Items | 3.037 | 12.866 | 8.638 | 6.134 | 3.917 |
Cash Interest Paid | 1.011 | 2.495 | 1.549 | 0.951 | 0.393 |
Changes in Working Capital | 6.068 | -29.049 | -1.227 | -4.219 | -2.346 |
Cash From Investing Activities | 0.777 | 72.777 | 54.179 | 43.724 | 22.629 |
Capital Expenditures | -15 | -0.45 | -0.377 | -0.188 | -0.224 |
Other Investing Cash Flow Items, Total | 15.777 | 73.227 | 54.556 | 43.912 | 22.853 |
Cash From Financing Activities | 19.123 | 6.55 | 8.646 | 3.135 | 8.797 |
Issuance (Retirement) of Stock, Net | 0.001 | 2.124 | 1.539 | 1.539 | 0.94 |
Net Change in Cash | 15.826 | 5.569 | 10.976 | 8.311 | 5.789 |
Financing Cash Flow Items | -0.828 | -15.116 | -12.435 | -8.346 | -2.118 |
Issuance (Retirement) of Debt, Net | 19.95 | 19.542 | 19.542 | 9.942 | 9.975 |
差價合約交易計算器
計算您的假設損益
交易佣金
0
- 1:1
槓桿
1:1
- 20
- 100
- 500
- 1000
- 10000
交易
交易規模(槓桿 x 投資):
打開
拋售
已賣出 做多
Industry: | Bio Therapeutic Drugs |
611 Gateway Boulevard, Suite 900
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
盈虧控制
- Annual
- Quarterly
人們也觀看
還在尋找值得信賴的經紀商?
加入全球 580.000 多名交易者,選擇與 Capital.com 交易